Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › irinotecan

irinotecan

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of irinotecan

145 trials tracked of irinotecan: 22 in phase 3 or 4 and 11 with published results. The most-cited published study has 1127 citations.

145Trials tracked
22Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 2 Phase 3 20 Phase 2 106 Phase 1 17
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,127 cited
  2. Phase 3 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer Completed · 592 cited
  3. Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Completed · 567 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 501 cited
  5. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 325 cited
  6. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 195 cited
Show 44 more trials
  1. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 181 cited
  2. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  3. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 48 cited
  4. Phase 4 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed · 18 cited
  5. Phase 3 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed · 1 cited
  6. Phase 4 A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum Completed
  7. Phase 3 Colorectal Cancer Metastatic Completed
  8. Phase 3 A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer Completed
  9. Phase 3 Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Completed
  10. Phase 3 Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer Completed
  11. Phase 3 A Study in Second Line Metastatic Colorectal Cancer Completed
  12. Phase 3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Completed
  13. Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
  14. Phase 3 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Completed
  15. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  16. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  17. Phase 2 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Completed
  18. Phase 2 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed
  19. Phase 2 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Completed
  20. Phase 2 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Completed
  21. Phase 2 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed
  22. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  23. Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Completed
  24. Phase 2 Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab Completed
  25. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  26. Phase 2 A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI Completed
  27. Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
  28. Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
  29. Phase 2 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Completed
  30. Phase 2 Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer Completed
  31. Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
  32. Phase 2 ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer Completed
  33. Phase 2 Irinotecan Study For Cervical Cancer Completed
  34. Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed
  35. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
  36. Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed
  37. Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
  38. Phase 2 A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer Completed
  39. Phase 2 Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery Completed
  40. Phase 2 Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer Completed
  41. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  42. Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
  43. Phase 2 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas Completed
  44. Phase 2 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Completed

Showing the 50 most-cited and recently-updated of 145 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy
Oncology Phase II
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy A New Second-Line Combo Shows Promise for Advanced Colon Cancer
This multicenter, single-arm, phase II trial evaluated biweekly trifluridine/tipiracil, irinotecan, and bevacizumab in 60 patients with meta…
For patients whose advanced colon cancer has stopped responding to initial chemo, a new drug combination is showing it can effectively fight…
Apr 12, 2026